Shots:

• Vir will receive ~$225M up front- $120M as an equity investment and $200M as regulatory milestones- ~300M as option payment and will be responsible to fund the development of VIR-2482 through the completion of the P-II trial
• GSK to get an exclusive option to co-develop VIR-2482 after Vir completes and reports P-II trial outcomes- and will share development costs on the development of all other influenza mAbs
• The new collaboration will engage the companies in two research programs. The first for functional genomics collaboration expanded to include respiratory viruses and others to develop up to three mAb to target non-influenza pathogens

 ­ Ref: GlobeNewswire | Image: GSK